Muraglitazar is a new drug developed to both lower blood glucose levels and improve blood lipids in patients with type 2 diabetes. On September 9, 2005, a US Food and Drug Administration (FDA) advisory panel strongly recommended approval of muraglitazar, and on October 18, 2005, the FDA issued an "approvable letter" for the drug. However, in a review of data from Phase 2 and 3 trials conducted by the drug manufacturer and provided to the FDA, Nissen and colleagues found that muraglitazar was associated with an excess incidence of the composite endpoint of death, major adverse cardiovascular events, and congestive heart failure.

I thought this story was rather interesting, especially given the current state of affairs and the war on supplements. Ironic, huh? Since this story came out, I've only seen it on the news once and if I would have blinked I would have missed it. Now if this were SD, etc. from one of those "fly-by-night" companies, can you imagine the media's response.
I was thinging perhaps someone should inform the Amy Shipley's of the world about this drug, you know, because she is so concerned about the public health of America.